Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00003346 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2013-06-25
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy consisting of acetaminophen plus carmustine in treating patients who have stage III or stage IV melanoma.
Conditions
- Melanoma (Skin)
Interventions
- DRUG
- DRUG
-
acetylcysteine
- DRUG
-
carmustine
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Paul B. Chapman, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-11-30
- Primary Completion
- 2003-02-28
- Completion
- 2003-02-28
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
NCT00003027 ·Status: COMPLETED ·Phase: PHASE3
-
Dacarbazine and Carmustine in Metastatic Melanoma
NCT01692691 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00004141 ·Status: COMPLETED ·Phase: PHASE2
-
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
NCT00004152 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
NCT03026517 ·Status: COMPLETED ·Phase: PHASE1
-
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
NCT00110123 ·Status: TERMINATED ·Phase: PHASE3
-
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
NCT04625205 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
NCT04162015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00002669 ·Status: COMPLETED ·Phase: PHASE2
-
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
NCT00243061 ·Status: COMPLETED ·Phase: PHASE2
-
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
NCT00005961 ·Status: COMPLETED ·Phase: PHASE2
-
CCI-779 in Treating Patients With Metastatic Melanoma
NCT00022464 ·Status: COMPLETED ·Phase: PHASE2
-
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
NCT00030082 ·Status: COMPLETED ·Phase: PHASE1
-
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00006237 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT01638676 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106 ·Status: RECRUITING ·Phase: PHASE3
-
CP-461 in the Treatment of Patients With Advanced Melanoma
NCT00060710 ·Status: TERMINATED ·Phase: PHASE2
-
Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
NCT00003509 ·Status: TERMINATED ·Phase: PHASE2
-
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
NCT00017121 ·Status: COMPLETED ·Phase: PHASE1
-
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
NCT02507076 ·Status: WITHDRAWN ·Phase: NA
-
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
NCT01359956 ·Status: COMPLETED ·Phase: PHASE3
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
E7070 in Treating Patients With Stage IV Melanoma
NCT00014625 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
NCT02141542 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT04007588 ·Status: WITHDRAWN ·Phase: PHASE2